Table 1 MCL-1 targeted anti-tumor drugs in clinical trials
From: Targeting MCL-1 in cancer: current status and perspectives
Agents | Frist report time (drug discovery method) | Identifier/phase | Population | Regimen |
|---|---|---|---|---|
Monotherapy | ||||
S64315 (MIK665) |
2016 (NMR-based fragment screen) | NCT02979366 Phase 1 | AML, MDS | Once or twice a week (21/28-day cycle), the starting dose is 50Â mg (intravenous) |
NCT02992483 Phase 1 | MM, DLBCL | Dose finding (intravenous) | ||
AZD5991 |
2018 (NMR-based fragment screen and Structure-based design) | NCT03218683 Phase 1 | AML, CLL, MDS, MM | Intravenously for 9 cycles (21-day cycle) |
AMG-176 |
2016 (High-throughput screening) | NCT02675452 (Suspended)Phase 1 | MM, AML | Dose finding(intravenous) |
AMG-397 |
2018 (-) | NCT03465540 (Suspended)Phase 1 | MM, NHL, AML, DLBCL | Once a day for 2 consecutive days followed by 5Â days break at a weekly interval (28-day cycle) (oral) |
ABBV-467 | NA | NCT04178902 Phase 1 2019 | MM and Cancer | Dose finding (intravenous) |
PRT1419 | NA | NCT04543305 Phase 1 2020 | MM, NHL, AML, MDS | Dose finding (oral) |
Combination therapy | ||||
S64315 + Venetoclaxv |  | NCT03672695 Phase 1 | AML | S64315 once a week (intravenous) Venetoclax once a day (oral) (21-day cycle) |
AZD5991 + Venetoclaxv |  | NCT03218683 Phase 2 | AML, MDS | Ascending oral doses of Venetoclax |
AMG-176 + Venetoclaxv |  | NCT03797261 (Suspended)Phase 1 | AML, NHL/DLBCL | Two-consecutive days per week (QD2) |
